SCHEMBL4833898

SCHEMBL4833898

COc1ccccc1C(=O)Nc1ccc(N2C=Nc3sccc3C2N)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 11/20 0.50
▸ TP53 P04637 4/20 0.50
▸ SMN1; SMN2 Q16637 5/20 0.48
▸ RAB9A P51151 4/20 0.48
▸ LMNA P02545 2/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ AHR P35869 1/20 0.48
▸ GFER P55789 1/20 0.48
▸ ALDH1A1 P00352 3/20 0.45
▸ HPGD P15428 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ MAPK1 P28482 3/20 0.43
▸ TSHR P16473 1/20 0.43
▸ KMT2A Q03164 4/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ KCNK3 O14649 1/20 0.43
▸ KCNK9 Q9NPC2 1/20 0.43
▸ POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4831435 0.81 NPC1 (0.51) MAPTTP53SMN1; SMN2RAB9ALMNA
SCHEMBL4826358 0.78 GRM4 (0.34) MAPTTP53SMN1; SMN2RAB9ALMNA
SCHEMBL4829077 0.77 NPY2R (0.43) KMT2AMEN1
SCHEMBL4826281 0.76 RAB9A (0.48) MAPTTP53SMN1; SMN2RAB9ANPC1
SCHEMBL4834612 0.76 BAZ1A (0.41) MAPTSMN1; SMN2NPC1ALDH1A1KMT2A
SCHEMBL4825704 0.75 TRPV1 (0.48) MAPTTP53SMN1; SMN2LMNAKMT2A
SCHEMBL4829300 0.74 HDAC1 (0.43) MAPTRAB9ALMNANPC1ALDH1A1
SCHEMBL4833679 0.74 GRM5 (0.47) —
SCHEMBL4825766 0.72 MAPK8 (0.47) SMN1; SMN2RAB9AALDH1A1KMT2AMEN1
SCHEMBL4833491 0.72 MAOA (0.49) MAPTTP53SMN1; SMN2RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP claimed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK MAPT 2499/4885TP53 54/4885SMN1; SMN2 4268/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR MAPT 2424/4885TP53 144/4885SMN1; SMN2 3836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback